RxDoctor Payments Data

David Lee, MD

Ophthalmology · Freehold, NJNPI 1225359847

Payments from drug & device makers

$2,304in general payments, 2019–2025

Across 37 payments — averaging $62.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Alcon$324
  • Apellis Pharmaceuticals, Inc.$139
  • AbbVie$67
  • Sun Pharmaceutical Industries Inc.$64
  • Akorn Operating Company LLC$52
  • plus $159 from 9 others

What the payments were for

  • Consulting fees$1,50065%
  • Food & beverage$78234%
  • Education$221%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,304 in reported general payments places this provider in the 60th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$337,082
Medicare patients
806
Services billed
2,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine61$88,611
LumiganBimatoprost167$85,751
RocklatanNetarsudil Mesylat/Latanoprost61$33,560
XiidraLifitegrast17$26,872
Cyclosporine40$26,399
VyzultaLatanoprostene Bunod42$25,765
CombiganBrimonidine Tartrate/Timolol43$25,435
Travoprost65$15,994
Prednisolone Acetate282$12,827
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$11,926
Latanoprost820$11,293
SimbrinzaBrinzolamide/Brimonidine Tart33$10,752
ZioptanTafluprost/Pf16$10,031
RhopressaNetarsudil Mesylate22$9,386
Alphagan PBrimonidine Tartrate11$8,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$67$208,766282 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$16$52,63759 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$13$42,94683 claims
AlconSimbrinza$324$10,75233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Freehold

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →